Zoetis Inc. Class A Common Stoc (ZTS) 46.51 $ZTS
7 Profitable Medical Stocks Ranked as Buys Now
Arpita Dutt - Zacks Investment Research - Tue Jun 21, 2:52PM CDT
It may be tough going for medical stocks but these 7 companies sporting a favorable Zacks Rank are poised to generate profits this year.
ZTS: 46.51 (-1.39), JNJ: 115.63 (-1.75), PFE: 33.97 (-0.62), LGND: 111.79 (-3.32), BMY: 70.61 (-2.03), AMPH: 15.61 (-0.54)
Can Zoetis (ZTS) Keep the Earnings Streak Alive This Quarter?
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 7:55AM CDT
Zoetis (ZTS) boasts a favorable Zacks Rank and a positive Earnings ESP, which is a great sign of a coming earnings beat.
ZTS: 46.51 (-1.39)
5 Top ROE Stocks for Improving Your Portfolio Returns
Zacks Equity Research - Zacks Investment Research - Thu Jun 16, 5:43AM CDT
With an enviable cash pile, these stocks appear to be enterprising picks when they are blended with attractive features like high ROE, high ROA and solid historical earnings growth along with a solid Zacks Rank.
ZTS: 46.51 (-1.39), BAK: 11.39 (-0.63), MO: 67.02 (+0.71), LEA: 104.78 (-11.09)
Zoetis to Participate in the William Blair 36th Annual Growth Stock Conference
BusinessWire - Wed May 18, 7:30AM CDT
Zoetis Inc.(NYSE:ZTS) will participate in the William Blair 36th Annual Growth Stock Conference on Tuesday, June 14, 2016, in Chicago, Ill. Juan Ramon Alaix, Chief Executive Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 10:30 a.m. EDT (9:30 a.m. CDT).
ZTS: 46.51 (-1.39)
Happy 4th for Fido? New doggy med for noise-related anxiety
By LINDA A. JOHNSON - AP - Mon May 16, 6:07PM CDT
Fido and Spot may not have to cower under the bed this summer when fireworks and thunderstorms hit.
ZTS: 46.51 (-1.39), PFE: 33.97 (-0.62)
Business Highlights
By The Associated Press - AP - Mon May 16, 4:46PM CDT
___
ZTS: 46.51 (-1.39), AGN: 225.72 (-7.79), AMZN: 698.96 (-23.12), PFE: 33.97 (-0.62), GM: 28.35 (-1.47), ANAC: 99.06 (-0.14), BRK.B: 139.71 (-6.27), BRK.A: 209,852.00 (-8,998.00)
Zoetis Announces Launch of SILEO(R) for Treatment of Noise Aversion in Dogs
BusinessWire - Mon May 16, 7:30AM CDT
Dogs that experience fear and anxiety in response to loud noise such as fireworks, thunder, and construction work now have a new treatment option with the launch of SILEO(R) (dexmedetomidine oromucosal gel), the first and only medication approved by the U.S. Food and Drug Administration (FDA) for treatment of noise aversion in dogs. Noise aversion refers to the behavioral and clinical signs of fear and anxiety experienced by dogs in response to noise. SILEO, which is being marketed in the U.S. by Zoetis Inc. (NYSE:ZTS), is available from veterinarians by prescription and can be safely administered at home by pet owners to help calm dogs without sedating for the duration of noise events.
ZTS: 46.51 (-1.39)
Zoetis to Participate in the Goldman Sachs 37th Annual Global Healthcare Conference
BusinessWire - Fri May 13, 7:30AM CDT
Zoetis Inc.(NYSE:ZTS) will participate in the Goldman Sachs 37th Annual Global Healthcare Conference on Tuesday, June 7, 2016, in Rancho Palos Verdes, Calif. Paul Herendeen, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 2:20 p.m. EDT (11:20 a.m. PDT).
ZTS: 46.51 (-1.39)
Zoetis Declares Third Quarter 2016 Dividend
BusinessWire - Thu May 12, 3:15PM CDT
The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a third quarter 2016 dividend payable to holders of the company's common stock of $0.095 per share. The dividend is to be paid on Tuesday, Aug. 30, 2016, to holders of record on Thursday, June 30, 2016.
ZTS: 46.51 (-1.39)
Zoetis Holds Annual Meeting of Shareholders
BusinessWire - Thu May 12, 11:00AM CDT
Speaking to shareholders at the Zoetis Inc. (NYSE:ZTS) annual meeting today in Short Hills, N.J., Chief Executive Officer Juan Ramon Alaix highlighted the company's 2015 performance and strategies for future growth as the global market leader in animal health.
ZTS: 46.51 (-1.39)
The Zacks Analyst Blog Highlights: Zoetis, McKesson, Merck, Endo International and AmerisourceBergen
Zacks Equity Research - Zacks Investment Research - Wed May 04, 8:30AM CDT
The Zacks Analyst Blog Highlights: Zoetis, McKesson, Merck, Endo International and AmerisourceBergen
ZTS: 46.51 (-1.39), ABC: 75.44 (-2.11), ENDP: 14.85 (-0.99), MCK: 177.07 (-6.93), MRK: 55.88 (-1.80)
Zoetis (ZTS) Beats Q1 Earnings and Revenue Estimates
Zacks Equity Research - Zacks Investment Research - Wed May 04, 7:35AM CDT
Zoetis beat on first-quarter 2016 earnings.
ZTS: 46.51 (-1.39)
Zoetis beats Street 1Q forecasts
Automated Insights - Wed May 04, 6:14AM CDT
FLORHAM PARK, N.J. (AP) _ Zoetis Inc. (ZTS) on Wednesday reported first-quarter net income of $204 million.
ZTS: 46.51 (-1.39)
Zoetis Reports First Quarter 2016 Results
BusinessWire - Wed May 04, 6:00AM CDT
--First Quarter 2016 Adjusted Net Income of $239 Million, or Adjusted Diluted EPS of $0.48
ZTS: 46.51 (-1.39)
Conatus (CNAT): Can the Stock Surprise in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue May 03, 5:57PM CDT
Conatus (CNAT) is scheduled to report first-quarter 2016 results on May 5, before market opens.
ZTS: 46.51 (-1.39), IPXL: 29.26 (-1.07), CNAT: 2.04 (-0.09), JAZZ: 137.90 (-7.10)
What's Up at GW Pharmaceuticals (GWPH) in Q2 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue May 03, 5:45PM CDT
GW Pharmaceuticals (GWPH), which is set to report second-quarter fiscal 2016 results on May 5, had posted a positive surprise of 34.78%.
ZTS: 46.51 (-1.39), IPXL: 29.26 (-1.07), GWPH: 83.31 (-5.83), JAZZ: 137.90 (-7.10)
Will AVEO Pharmaceuticals (AVEO) Surprise in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue May 03, 5:42PM CDT
AVEO Pharmaceuticals (AVEO) is expected to report first-quarter 2016 results on Mar 5.
ZTS: 46.51 (-1.39), OPHT: 51.99 (-3.89), AVEO: 0.95 (-0.03), NVS: 77.10 (-3.57)
Drug Stocks Reporting Mid-Week: MRK, ABC, ENDP & More
Arpita Dutt - Zacks Investment Research - Tue May 03, 8:50AM CDT
Major drug companies like Merck (MRK) and McKesson (MCK) will be reporting this week.
ZTS: 46.51 (-1.39), ABC: 75.44 (-2.11), ENDP: 14.85 (-0.99), MCK: 177.07 (-6.93), MRK: 55.88 (-1.80), EXEL: 7.69 (-0.16)
Celldex (CLDX): What's Ahead for the Stock in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Mon May 02, 10:52AM CDT
Celldex (CLDX) is expected to report first-quarter 2016 results on May 4.
ZTS: 46.51 (-1.39), CLDX: 4.36 (-0.21), GNCA: 4.19 (-0.48), BMY: 70.61 (-2.03)
What's Up at Ionis Pharmaceuticals (IONS) in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Mon May 02, 10:37AM CDT
Ionis Pharmaceuticals (IONS) is scheduled to report first-quarter 2016 results on May 4.
ZTS: 46.51 (-1.39), BIIB: 229.02 (-9.60), GSK: 40.80 (-1.76), IONS: 21.97 (-1.63)
7 Profitable Medical Stocks Ranked as Buys Now
Arpita Dutt - Zacks Investment Research - Tue Jun 21, 2:52PM CDT
It may be tough going for medical stocks but these 7 companies sporting a favorable Zacks Rank are poised to generate profits this year.
ZTS: 46.51 (-1.39), JNJ: 115.63 (-1.75), PFE: 33.97 (-0.62), LGND: 111.79 (-3.32), BMY: 70.61 (-2.03), AMPH: 15.61 (-0.54)
Can Zoetis (ZTS) Keep the Earnings Streak Alive This Quarter?
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 7:55AM CDT
Zoetis (ZTS) boasts a favorable Zacks Rank and a positive Earnings ESP, which is a great sign of a coming earnings beat.
ZTS: 46.51 (-1.39)
5 Top ROE Stocks for Improving Your Portfolio Returns
Zacks Equity Research - Zacks Investment Research - Thu Jun 16, 5:43AM CDT
With an enviable cash pile, these stocks appear to be enterprising picks when they are blended with attractive features like high ROE, high ROA and solid historical earnings growth along with a solid Zacks Rank.
ZTS: 46.51 (-1.39), BAK: 11.39 (-0.63), MO: 67.02 (+0.71), LEA: 104.78 (-11.09)
Zoetis to Participate in the William Blair 36th Annual Growth Stock Conference
BusinessWire - Wed May 18, 7:30AM CDT
Zoetis Inc.(NYSE:ZTS) will participate in the William Blair 36th Annual Growth Stock Conference on Tuesday, June 14, 2016, in Chicago, Ill. Juan Ramon Alaix, Chief Executive Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 10:30 a.m. EDT (9:30 a.m. CDT).
ZTS: 46.51 (-1.39)
Happy 4th for Fido? New doggy med for noise-related anxiety
By LINDA A. JOHNSON - AP - Mon May 16, 6:07PM CDT
Fido and Spot may not have to cower under the bed this summer when fireworks and thunderstorms hit.
ZTS: 46.51 (-1.39), PFE: 33.97 (-0.62)
Business Highlights
By The Associated Press - AP - Mon May 16, 4:46PM CDT
___
ZTS: 46.51 (-1.39), AGN: 225.72 (-7.79), AMZN: 698.96 (-23.12), PFE: 33.97 (-0.62), GM: 28.35 (-1.47), ANAC: 99.06 (-0.14), BRK.B: 139.71 (-6.27), BRK.A: 209,852.00 (-8,998.00)
Zoetis Announces Launch of SILEO(R) for Treatment of Noise Aversion in Dogs
BusinessWire - Mon May 16, 7:30AM CDT
Dogs that experience fear and anxiety in response to loud noise such as fireworks, thunder, and construction work now have a new treatment option with the launch of SILEO(R) (dexmedetomidine oromucosal gel), the first and only medication approved by the U.S. Food and Drug Administration (FDA) for treatment of noise aversion in dogs. Noise aversion refers to the behavioral and clinical signs of fear and anxiety experienced by dogs in response to noise. SILEO, which is being marketed in the U.S. by Zoetis Inc. (NYSE:ZTS), is available from veterinarians by prescription and can be safely administered at home by pet owners to help calm dogs without sedating for the duration of noise events.
ZTS: 46.51 (-1.39)
Zoetis to Participate in the Goldman Sachs 37th Annual Global Healthcare Conference
BusinessWire - Fri May 13, 7:30AM CDT
Zoetis Inc.(NYSE:ZTS) will participate in the Goldman Sachs 37th Annual Global Healthcare Conference on Tuesday, June 7, 2016, in Rancho Palos Verdes, Calif. Paul Herendeen, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 2:20 p.m. EDT (11:20 a.m. PDT).
ZTS: 46.51 (-1.39)
Zoetis Declares Third Quarter 2016 Dividend
BusinessWire - Thu May 12, 3:15PM CDT
The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a third quarter 2016 dividend payable to holders of the company's common stock of $0.095 per share. The dividend is to be paid on Tuesday, Aug. 30, 2016, to holders of record on Thursday, June 30, 2016.
ZTS: 46.51 (-1.39)
Zoetis Holds Annual Meeting of Shareholders
BusinessWire - Thu May 12, 11:00AM CDT
Speaking to shareholders at the Zoetis Inc. (NYSE:ZTS) annual meeting today in Short Hills, N.J., Chief Executive Officer Juan Ramon Alaix highlighted the company's 2015 performance and strategies for future growth as the global market leader in animal health.
ZTS: 46.51 (-1.39)
The Zacks Analyst Blog Highlights: Zoetis, McKesson, Merck, Endo International and AmerisourceBergen
Zacks Equity Research - Zacks Investment Research - Wed May 04, 8:30AM CDT
The Zacks Analyst Blog Highlights: Zoetis, McKesson, Merck, Endo International and AmerisourceBergen
ZTS: 46.51 (-1.39), ABC: 75.44 (-2.11), ENDP: 14.85 (-0.99), MCK: 177.07 (-6.93), MRK: 55.88 (-1.80)
Zoetis (ZTS) Beats Q1 Earnings and Revenue Estimates
Zacks Equity Research - Zacks Investment Research - Wed May 04, 7:35AM CDT
Zoetis beat on first-quarter 2016 earnings.
ZTS: 46.51 (-1.39)
Zoetis beats Street 1Q forecasts
Automated Insights - Wed May 04, 6:14AM CDT
FLORHAM PARK, N.J. (AP) _ Zoetis Inc. (ZTS) on Wednesday reported first-quarter net income of $204 million.
ZTS: 46.51 (-1.39)
Zoetis Reports First Quarter 2016 Results
BusinessWire - Wed May 04, 6:00AM CDT
--First Quarter 2016 Adjusted Net Income of $239 Million, or Adjusted Diluted EPS of $0.48
ZTS: 46.51 (-1.39)
Conatus (CNAT): Can the Stock Surprise in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue May 03, 5:57PM CDT
Conatus (CNAT) is scheduled to report first-quarter 2016 results on May 5, before market opens.
ZTS: 46.51 (-1.39), IPXL: 29.26 (-1.07), CNAT: 2.04 (-0.09), JAZZ: 137.90 (-7.10)
What's Up at GW Pharmaceuticals (GWPH) in Q2 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue May 03, 5:45PM CDT
GW Pharmaceuticals (GWPH), which is set to report second-quarter fiscal 2016 results on May 5, had posted a positive surprise of 34.78%.
ZTS: 46.51 (-1.39), IPXL: 29.26 (-1.07), GWPH: 83.31 (-5.83), JAZZ: 137.90 (-7.10)
Will AVEO Pharmaceuticals (AVEO) Surprise in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue May 03, 5:42PM CDT
AVEO Pharmaceuticals (AVEO) is expected to report first-quarter 2016 results on Mar 5.
ZTS: 46.51 (-1.39), OPHT: 51.99 (-3.89), AVEO: 0.95 (-0.03), NVS: 77.10 (-3.57)
Drug Stocks Reporting Mid-Week: MRK, ABC, ENDP & More
Arpita Dutt - Zacks Investment Research - Tue May 03, 8:50AM CDT
Major drug companies like Merck (MRK) and McKesson (MCK) will be reporting this week.
ZTS: 46.51 (-1.39), ABC: 75.44 (-2.11), ENDP: 14.85 (-0.99), MCK: 177.07 (-6.93), MRK: 55.88 (-1.80), EXEL: 7.69 (-0.16)
Celldex (CLDX): What's Ahead for the Stock in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Mon May 02, 10:52AM CDT
Celldex (CLDX) is expected to report first-quarter 2016 results on May 4.
ZTS: 46.51 (-1.39), CLDX: 4.36 (-0.21), GNCA: 4.19 (-0.48), BMY: 70.61 (-2.03)
What's Up at Ionis Pharmaceuticals (IONS) in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Mon May 02, 10:37AM CDT
Ionis Pharmaceuticals (IONS) is scheduled to report first-quarter 2016 results on May 4.
ZTS: 46.51 (-1.39), BIIB: 229.02 (-9.60), GSK: 40.80 (-1.76), IONS: 21.97 (-1.63)
